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ABSTRACT
OBJECTIVE: The aim of the present study was to reveal the possible effect of sulforaphane on oxidative stress 
and infl ammation in rats liver with toxic hepatitis induced by acetaminophene.
BACKGROUND: Sulforaphane is a compound with high antioxidant properties. Acetaminophen, which is a 
para-aminophenol derivative, can lead to fatal hepatic necrosis with direct hepatotoxic effects at high doses. 
METHODS: Thirty six male Sprague-Dawley rats were randomly divided into four groups. Control group (n = 9) 
was fed with standard rat chow and water for 3 days. Group APAP (n = 9) received a single dose acetamino-
phen 1 g/kg by oral gavage in addition to standard chow and water. Group SFN (n = 9) received sulforaphane 
500 μg/kg by oral gavage in addition to standard chow and water for 3 days. Group APAP+SFN (n = 9) received 
sulforaphane 500 μg/kg and a single dose acetaminophen 1 g/kg by oral gavage in addition to standard chow 
and water. Acetaminophen was administered three hours after SFN administration. 
RESULTS: Neopterin, MDA, AST, ALT and CRP levels of group APAP were signifi cantly increased compared to 
control group. GSH level of group APAP was signifi cantly lower than in the control group.
CONCLUSION: Sulforaphane is a protective agent against acetaminophen-induced liver damage and it can be 
added in the treatment protocol (Tab. 1, Fig. 5, Ref. 51). Text in PDF www.elis.sk.
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Highlights
• The analgesic acetaminophen causes a potentially fatal hepato-
toxicity when taken in overdose. 
• Sulforaphane has a protective effect on the liver.
• SFN has preventive action in lipid peroxidation on liver injury.
• Neopterin is a biomarker for the animal model of APAP-induced 
liver injury.
Introduction
Due to its strategic role in the body, the liver is a key organ for 
metabolism, secretion and excretion of various xenobiotics, envi-
ronmental pollutants and chemotherapeutic agents that the body 
is exposed to. Liver damage and subsequent deaths remain to be 
a common concern worldwide (1, 2). Hepatotoxicity as a result of 
unconsciously used drugs is one of the common causes of acute 
liver damage. Studies have shown that 58 % of acute liver failure 
is caused by drugs, and acetaminophen (APAP) takes a signifi cant 
place among these drugs (3).
Acetaminophen, which is a para-aminophenol derivative, can 
lead to fatal hepatic necrosis with direct hepatotoxic effects at high 
doses. For individuals with alcohol abuse and malnutrition, the 
use of acetaminophen even at treatment doses may cause asymp-
tomatic transferase elevation or hepatotoxicity. Acetaminophen 
toxicity impairs the mechanism of liver detoxifi cation. Glutathi-
one (GSH) stores become inadequate when taken in overdose and 
N-acetyl-p-benzoquinone (NAPQI) which is a toxic metabolite of 
acetaminophene causes hepatocellular necrosis by binding to the 
cytoplasmic proteins (3, 4, 5). Although the exact mechanism of 
the hepatic damage is not fully clarifi ed, oxidative damage is the 
most underlined factor. Increased oxidative stress causes impair-
ment of intracellular calcium homeostasis, signal transduction and 
mitochondrial permeability, and eventually ceases production of 
adenosine triphosphate (ATP). As a result of all these factors, cell 
necrosis occurs (4, 6). Malondialdehyde (MDA) is the most com-
monly used marker for oxidative damage. MDA, the end product 
of lipid peroxidation, affects ion exchange in the membrane by 
increasing cell membrane permeability. As a result, intracellular 
ion balance is disturbed, causing impairment of enzyme activities. 
It leads to tissue damage both in its own region of formation and 
in further remote regions that it diffused to (7). 
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It is not always easy to predict hepatotoxicity because it ex-
hibits variations depending on the sensitivity of the person as well 
as the drug used. Therefore, early diagnosis is very important in 
hepatotoxicity to achieve a more effective treatment. C-reactive 
protein (CRP) is an acute-phase reactant that is mainly synthesized 
by hepatocytes in the liver as part of an infl ammatory response. 
CRP plays an important role in the infl ammatory process, and as 
such could potentially be affected by liver disease (8). Neopterin, 
a pyrazinopyrimidine compound, is used as a very popular bio-
marker especially in important pathologies where cellular immu-
nity mechanisms are actived. It is remarkable because it is easily 
measurable and it serves as a guide in the evaluation of diagnosis, 
prognosis and treatment effi cacy (9, 10). Various studies reported 
that neopterin can be used as an important biomarker in many sys-
temic toxicities and pathologies and as a new biomarker in liver 
diseases (11, 12). Many studies indicated that neopterin was asso-
ciated with interactions between both reactive oxygen metabolites 
and oxidative stress. Neopterin plays a role in the defense system 
by increasing the cytotoxic effects of reactive oxygen metabo-
lites that are formed in the body against invasive pathogens. The 
increase in serum levels of neopterin along with the increase in 
severity of infl ammation, infection, and malignancy indicate that 
neopterin is part of the defense system (6, 13).
Antioxidant defense mechanisms are developed in the body to 
prevent the formation and damage of free radicals. In the case of 
hepatotoxicity, free radical production increases and antioxidant 
defense mechanisms become insuffi cient (6). Sulforaphane (SFN) 
is a compound with high antioxidant properties present in broccoli. 
Recent studies report that sulforaphane is safe and tolerable and 
exhibits its benefi cial effects by activating liver phase II detoxi-
fi cation enzymes. Sulforaphane is considered as a potent fi ghter 
against oxidative stress with its antioxidant, anti-infl ammatory and 
anti-tumor effects (13, 14). In this study, we intended to investi-
gate whether sulforaphane is protective against acetaminophen-
induced liver damage or not, by evaluating the levels of neopterin, 
a cellular immunosystem activation marker, as well as CRP, lipid 
peroxidation and glutathione levels. 
Materials and methods
Chemicals
APAP and SFN were purchased from Sigma Chemical Co (St. 
Louis, MO, Germany).
Experimental animals 
Randomly selected 36 male Sprague-Dawley rats were used 
in the study, each about 200–250 g and 6–8 weeks of age. The 
animals were housed in special rooms with ambient temperature 
of 22 ± 2 °C and humidity of 50–60 %, under photoperiod of 12: 
12 h light: dark and were given tap water and standard diet. This 
study was carried out in the Atatürk University’s Experimental 
Animal Laboratory of the Medical and Experimental Application 
and Research (ATADEM) in accordance of the Atatürk Univer-
sity’s Local Ethical committee decision of date 30.04.2014 and 
the project number of 2014/63.
Experimental groups 
The study consisted of four groups, each including nine rats, 
namely control group, acetaminophen (APAP) group, sulfora-
phane (SFN) group and APAP+SFN group. Experimental studies 
continued for three days. Nothing was given to the control group 
throughout the experiment. SFN was administered for treatment 
via oral gavage at a dose of 500 μg/kg for three days to the rats of 
SFN and APAP+SFN groups (15). Acetaminophen was dissolved 
in hot saline and administered on the third day to produce toxic 
hepatitis via a single oral gavage at a dose of 1 g/kg to the rats of 
the APAP and APAP+SFN groups (16). APAP was administered 
three hours after SFN administration in the APAP+SFN group.
Preparation of serum and tissue samples
At the end of the experiment, the rats were anesthetized by in-
traperitoneal injection of a mixture of ketamine hydrochloride (60 
mg/kg) and xylazine (12 mg/kg) and sacrifi ced 24 hours after the 
last administration. Animals were anesthetized by intraperitoneal 
injection of a mixture of ketamine hydrochloride (60 mg/kg) and 
xylazine (12 mg/kg).Their blood was collected into biochemical 
tubes by heart puncture. Blood samples were centrifuged for 10 
minutes at 3500 rpm to obtain a clear serum, which was stored at 
–80 °C. Serum samples were used to determine the activities of 
aspartate aminotransferase (AST), alanine aminotransferase (ALT) 
and CRP. The liver tissue was excised immediately and washed 
with icecold saline. Liver tissues were homogenized with 0.1 M 
phosphate buffer at pH 7.4. (17). The homogenates were used 
to determine the total protein, MDA, GSH and neopterin levels.
Biochemical analyses
Hepatotoxicity was assessed by quantifying the serum activi-
ties of AST and ALT. AST, ALT and CRP levels were measured 
using a modular autoanalyzer (Roche, Mannheim, Germany). 
The results of AST and ALT were expressed as U/L. The results 
of CRP was expressed as mg/dl. Hepatic MDA levels were mea-
sured spectrophotometrically based on the method described by 
Ohkawa et al (18). Then, 0.5 mL of 8.1 % sodium dodecyl sulfate 
(SDS), 0.5 mL of 0.8 % thiobarbituric acid (TBA), 1.0 mL of 10 
% of trichloracetic acid (TCA), 1.0 mL of 2 % glacial acetic acid/
sodium hydroxide (NaOH) (pH = 3.5) and 50 μL of 2 % butylhy-
droxytoluene (BHT) were added to the samples (1.0 mL) and this 
mixture was thoroughly mixed and kept in a water-bath at 95 °C 
for 60 mins. After the tubes had been chilled, a mixture of 4.0 mL 
of butanol/pyridine (1 : 15) was added and the tubes were centri-
fuged at 4000× g at +4 °C for 10 mins. After centrifugation, the 
upper organic phase was removed and the absorbance was read 
at 532 nm for all samples. MDA results were expressed as nmol/
mg protein. Hepatic GSH levels were also measured spectropho-
tometrically based on the method described by Beutler et al (19). 
The spectrophotometric assay method for glutathione (GSH) in-
volved oxidation of GSH by the sulfhydryl reagent 5,5’-dithio-
bis (2-nitrobenzoic acid) (DTNB) to form the yellow derivative 
5’thio-2-nitrobenzoic acid (TNB), measurable at 412 nm. GSH 
results were expressed as nmol/mg protein. Tissue protein analysis 
was done by the method described by Lowry et al (20). Hepatic 
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neopterin levels were measured by using the enzyme-linked im-
munoassay (ELISA) method using a rat ELISA kit (Shangai Yehua 
Biological Technology Co., Ltd., Shanghai, China) according to 
the manufacturer’s recommended test procedure. Neopterin results 
were expressed as nmol/mg protein.
Tissue histology
Samples of liver tissue from each animal were fi xed in 10 % 
formalin, dehydrated in ascending grades of alcohol and embedded 
in paraffi n. Slides were examined under the microscope to detect 
histologic changes subsequent to staining with haematoxylin and 
eosin (H & E).
Statistical analysis
All data analyses were performed by using Statistical Pack-
age for the Social Sciences (SPSS) for Windows 19.0 package 
program (SPSS Inc., Chicago, IL, USA). Kolmogorov–Smirnov 
test was done to evaluate the distribution of variables. Continu-
ous normally distributed measurements were compared across the 
groups by using one-way analysis of variance (ANOVA) with the 
Tukey method and the Student–Newman–Keuls method multiple 
comparisons. The descriptive statistics were demonstrated by n 
(i.e., the sample size) and by the mean and standard deviation 
for continuous variables. A p < 0.05 was accepted as signifi cant.
Results
Biochemical results
Serum AST, ALT and CRP levels were determined to increase 
signifi cantly in the group of acetaminophen in comparison to the 
control group (respectively, p < 0.001) (Tab. 1). In the APAP+SFN 
group however, AST, ALT and CRP levels were observed to de-
crease statistically more signifi cantly than in the APAP group (p 
< 0.001), it was observed that they are signifi cantly higher than 
those in the control group (p < 0.05). No statistically signifi cant 
difference was determined in terms of AST, ALT and CRP levels 
in SFN group when compared to the controls (p > 0.05). 
Glutathione levels 
GSH levels showed a statistically signifi cant decrease in the 
APAP group compared to the control group (p < 0.001). Hepatic 
GSH levels in the APAP+SFN group were found to increase with 
respect to the APAP group (p < 0.001) while there was no sig-
nifi cant difference with respect to the control group (p > 0.05). 
However, there was no statistically signifi cant difference in the 
hepatic GSH levels of SFN group in comparison to the control 
group (p > 0.05). 
Lipid peroxidation 
Hepatic MDA levels in the APAP group increased signifi cantly 
when compared to the controls (p<0.001). In comparison to the 
APAP group, MDA levels showed a decrease in the APAP+SFN 
group (p<0.001). There was no statistically signifi cant difference 
in the hepatic MDA levels of the APAP+SFN group with respect to 
the control group (p>0.05). Hepatic MDA levels of the SFN group 
showed no statistically signifi cant difference when compared to 
the control group (p>0.05). 
Neopterin levels 
In our study, neopterin levels showed a signifi cant increase 
in the APAP group with respect to the control group (p < 0.001) 
whereas neopterin levels in APAP+SFN group were observed to de-
crease signifi cantly with respect to APAP group (p < 0.001) (Fig. 1). 
Neopterin levels of the APAP+SFN group showed no statistically 
signifi cant difference with respect to the control group (p > 0.05). 
There was no statistically signifi cant difference in neopterin levels 
of the SFN group when compared to the control group (p > 0.05).
Histology analysis
The livers of the control and SFN groups showed normal histo-
logical structure. The liver tissues showed portal triad, and normal 
Control APAP SFN APAP+SFN
AST (U/L) 69.33±7.80 142.33±6.94a 75.18±8.64d 82.25±9.18b,c
ALT (U/L) 34.00±2.87 95.00±6.25a 43.67±4.76d 53.61±5.21b,c
CRP (mg/dl) 3.42±0.10 15.61±2.14a 3.88±1.13d 6.52±0.98b,c
GSH(nmol/mg protein) 4.30±0.18 2.45±0.54a 4.22±0.10d 4.19±0.20b
MDA (nmol/mg protein) 9.90±2.27 17.92±4.24a 10.83±2.11d          9.79±3.10b
Data were given as mean ±SD, AST – Aspartate aminotransferase, ALT – Alanine aminotransferase, APAP – Acetaminophene, CRP – C-reactive protein; GSH – Glutathione, 
MDA – Malondialdehyde, SFN – Sulforaphane. a Signifi cantly different when compared with control group (p < 0.001), b Signifi cantly different when compared with APAP 
group (p < 0.001), c Signifi cantly different when compared with control group (p < 0.05), d Signifi cantly different when compared with control group (p > 0.05) 
Tab. 1. Biochemical parameters of the groups.
Fig. 1. Liver neopterin levels in experimental groups. * – signifi cantly 
different when compared with control group (p < 0.001), ** – Signifi -
cantly different when compared with APAP group, (p < 0.001).
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showed mild cellular infl ammation and the area of liver damage 
was reduced compared with APAP group. SFN treatment caused 
signifi cant changes in the liver histology and showed portal triad, 
normal arrangement of hepatocytes with nuclei and normal hepatic 
architecture (Fig. 5).
Discussion
One of the most important health problems on which the re-
searchers and pharmaceutical industry collaborate globally is the 
drug-induced liver diseases, and they are thought to be the result 
of direct hepatotoxicity and adverse immunological reactions. 
Understanding the mechanisms of action of hepatotoxicity in re-
lation with mortality is important for biological tracing of toxic 
compounds and developing treatment modalities. Drug-induced 
hepatotoxicity presents with a broad clinical spectrum, from mild 
biochemical abnormalites to acute hepatic failure (21, 22).
Fig. 2. Photomicrographs of rat liver (H and E, x100) from: control 
group showing normal hepatic architecture.
Fig. 3. Photomicrographs of rat liver (H and E, x100) from: sulfora-
phane group showing normal hepatic architecture.
Fig. 4. Photomicrographs of rat liver (H and E, x100) from: (a) acetaminophen group showing intense cellular degeneration, sinusoidal dilata-
tion and (b) cellular infl ammation of hepatocytes with vascular congestion.
A B
arrangement of hepatocytes with nuclei (Figs 2 and 3). APAP over-
dose caused marked liver damage in the form of intense cellular 
degeneration, sinusoidal dilatation and cellular infl ammation of 
hepatocytes with vascular congestion (Fig. 4). APAP+SFN group 
Fig. 5. Photomicrographs of rat liver (H and E, x100) from: acetamio-
phen plus sulforaphne group showing mild cellular infl ammation and 
normal arrangement of hepatocytes with nuclei, and showing normal 
hepatic architecture. The area of liver damage was reduced compared 
with acetaminophen group.
Dokumacioglu E et al. The effect of sulforaphane on oxidative stress and infl ammation… 
xx
457
APAP-induced hepatotoxicity is one of the leading causes of 
acute liver failure today. As the frequency of APAP use increases, 
the incidence of acute hepatic failure and mortality in overdos-
age is observed to increase as well (22). AST and ALT, which are 
key parameters of hepatocellular damage, are important routine 
hepatic tests assessing the presence and characteristics of the liver 
disease and the response to treatment (23). In our study, serum 
AST and ALT levels, which are indicative of hepatocellular dam-
age, increased signifi cantly in the toxic hepatitis group induced 
by APAP when compared to the control group. Sulforaphane 
however, was observed to reduce serum AST and ALT levels sig-
nifi cantly compared to the toxic hepatitis group. Many different 
medications can cause drug-induced liver diseases. Painkillers 
that contain acetaminophen are a common cause of liver infl am-
mation. These medications can damage the liver when taken in 
doses that are not much greater than the recommended dose (24). 
Infl ammation plays a critical role in liver disease via induction of 
cellular injury and CRP plays an important role in the infl ammatory 
process (8). In our study, serum CRP levels, which are indicative 
of infl ammatory response, increased signifi cantly in the hepato-
toxicity group induced by APAP when compared to the control 
group. Sulforaphane however, was observed to reduce serum CRP 
levels signifi cantly compared to the APAP-induced toxic hepatitis 
group. In this study, APAP-induced hepatotoxicity was evidenced 
by biochemical measurements and histopathological changes that 
coincided with the observations of other investigators.
Glutathione is a potent antioxidant highly found in hepato-
cytes, with a remarkable ability for free-radical scavenging in 
order to maintain cellular integrity and contribute to intracellular 
defense (25). Studies have reported that acetaminophen toxicity 
signifi cantly reduced hepatic GSH levels (26, 27). It was shown 
that reduction in intracellular GSH levels alone did not cause cell 
death by itself, but the depletion of GSH levels was determined to 
trigger the cytotoxicity (28). It was reported that reduction in GSH 
levels can cause formation of reactive oxygen species and mito-
chondrial dysfunction. In acetaminophen-induced hepatotoxicity, 
the depletion of GSH that can detoxify NAPQI reactive metabo-
lites is thought to play a role in the onset of liver damage (6, 29).
Antioxidants have a signifi cant protective role in the acet-
aminophen-induced liver damage (25). Sulforaphane is one of the 
natural antioxidants that has an effect on important cellular de-
fense systems (30). Santana-Martínez et al (31). It is reported that 
sulforaphane signifi cantly increased the GSH levels and plays a 
protective role against the oxidative stres. Also in our study, in line 
with the results in literature, we determined that sulforaphane had a 
protective role against acetaminophen-induced hepatotoxicity and 
GSH levels signifi cantly increased in the treatment group compared 
to the group with APAP-induced toxicity. GSH plays a key role in 
cellular defense systems. Dysregulation of GSH homeostasis plays 
a role in the etiology and progression of many diseases including 
cancer, aging, infl ammatory and neurodegenerative diseases (32, 
33). In their study, Baek et al (33) reported the protective effects 
of sulforaphane on CCl4-induced liver damage, and indicated that 
such effects were mediated by the induction of liver phase II en-
zymes. Likewise, in another study, increasing hepatic GSH levels 
were shown to be protective against hepatic damage in the group 
treated with sulforaphane before liver ischemia reperfusion (Zhao 
et al, 2010). Considering our results as well as those found in lit-
erature, we can say that sulforaphane protects the liver excellently 
by inducing GSH, which is a powerful cellular defense system 
against possible damages from various substances. 
Oxygen free radicals and lipid peroxidation, which play a role 
in the pathogenesis of various hepatic diseases, exhibit their direct 
damage by causing changes in membrane structure and indirect 
damage by leading to the formation of reactive aldehydes (34, 
35). As a result of such deterioration in the membrane structure, 
some changes occur in membrane functions such as ion transport 
and enzyme activity. Free radicals and lipid peroxides are admit-
ted to play a role in the development of various diseases such as 
diabetes, atherosclerosis, cancer and liver cirrhosis, while lipid 
peroxidation is suggested to be closely related to the tissue damage 
from acetaminophen-induced hepatotoxicity (36, 37). In addition, 
the superoxide radical and singlet oxygen are reported to induce 
liver damage through lipid peroxidation (38). Recent experimen-
tal hepatotoxicity studies demonstrated increased MDA levels in 
plasma and liver tissue (39, 40). The 4-hydroxynonenal molecule, 
which is a lipid peroxidation product and also an aldehyde, is re-
ported by Terneus et al (41) to be linked to liver tissue proteins in 
acetaminophen-induced groups. Based on our fi ndings and those 
found in literature; we can claim that increased MDA levels in 
acetaminophen-induced toxic hepatitis is one of the consequences 
of lipid peroxidation caused by free radicals. This result suggests 
that free radicals and oxidative stress play a role in tissue damage 
in toxic hepatitis. Increased lipid peroxidation products, especially 
aldehydes, can interact with various biomolecules, affecting their 
functions. In the light of the literature, increased MDA levels in the 
liver tissue in our study suggest that MDA will continue to have 
adverse effects both in the region it is formed and in remote tissues. 
All living organisms are constantly exposed to free radicals, 
both physiologically and through external factors. Free radical 
formation and lipid peroxidation is either a normal physiological 
state or a signal of disease development. The human body neu-
tralizes the oxidants by innate antioxidant defense mechanisms. 
However, in some cases innate antioxidant defense is not adequate. 
Exogenous antioxidants must be additionally taken (42, 43). To the 
best of our knowledge, there are very few studies investigating the 
effects of sulforaphan on acetaminophen-induced hepatotoxicity 
(26). Gaona-Gaona et al (15) experimentally induced liver dam-
age and reported that sulforaphane reduced the MDA levels in the 
liver by decreasing lipid peroxidation. In our study, we determined 
that sulforaphane signifi cantly decreased liver MDA levels in the 
treatment group compared to the hepatotoxicity group. The de-
creased MDA levels in the treatment group may suggest that sul-
foraphane can reduce oxidative stress-mediated liver damage and 
distal tissue damage. As a result, many diseases can be prevented 
and the duration and quality of life can be improved by avoiding 
free radicals and taking antioxidant-rich nutrients.
Recent studies indicated that serum or urine neopterin levels can 
be used as diagnostic and prognostic markers in various pathologic 
conditions (44, 45). Abnormal neopterin concentrations are shown 
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to be detected in body fl uids in various clinical situations, they are 
also reported to provide information about the current state of the 
cellular immune response and usually helpful in predicting disease 
progression (46). Increased neopterin levels indicate the endoge-
nous formation of gamma interferon and thus, monitoring neopter-
in levels allows the activation status of the cell-mediated immune 
system to be determined. Some xenobiotics, various viral, bacterial, 
infl ammatory and malign diseases, stressful factors such as physi-
cal changes and various infections can result in increased neopterin 
concentrations of biological fl uids such as urine and serum (47).
Macrophages as well as infl ammatory cytokines were reported 
in various studies to increase in the liver in acetaminophen-induced 
hepatic damage (48, 49). There is an inceasing interest towards ne-
opterin in recent years, which is regarded as a biochemical marker 
of cell-mediated immune response. So, in this study, based on the 
fact that neopterin is a marker of cellular immune response, we in-
vestigated the value of neopterin in early diagnosis of drug-related 
toxic hepatitis and whether it might be a criterion for initiating 
the treatment by determining neopterin levels, or not. Demirbas 
et al (11) reported increased neopterin levels in acetaminophene-
induced liver damage and argued that neopterin levels can be used 
as a new marker due to its preclinical features in these cases. In 
another study conducted by Cakir et al (48), nephrotoxicity was 
established by acetaminophen and neopterin levels were reported 
to be high. In adult patients with liver cirrhosis, Fernandez et al 
(50) found higher serum neopterin levels compared to the healthy 
control group. In parallel with the literature, we also found that 
neopterin levels were higher in the APAP-induced hepatotoxicity 
group with respect to the control group. Based on the literature 
and our data, as a sensitive indicator of cellular immunological 
activation of various diseases, increased levels of neopterin may 
be one of the factors responsible for the progression of APAP-in-
duced hepatotoxicity. Besides, increased neopterin levels may be 
also responsible for the development of irreversible hepatocellular 
damage (51). Gaonae Gaona L et al (15) reported that sulforaphane 
exhibits its hepatoprotective effects by protecting mitochondrial 
function and antioxidant enzymes and by preventing mitochondrial 
oxidative stress in the liver. There is no study in the literature show-
ing the effects of sulforaphane on neopterin levels in experimental 
liver damage. In our study, hepatic neopterin levels were found to 
be lower in the treatment group with respect to the hepatotoxic-
ity group. In addition, neopterin levels in this group decreased to 
the levels of the healthy control group. Which factors play a role 
in the progression of acetaminophen-induced liver damage is still 
uncertain. Focusing on various factors, new research studies are 
being carried out steadily. Macrophages as well as infl ammatory 
cytokines were reported in various studies to increase in the liver 
in acetaminophen-induced hepatic damage (48, 49). 
As a result, we obtained two important data. We can assert 
that sulforaphane administration in the acetaminophen-induced 
toxic hepatitis model is effective in reducing lipid peroxidation 
and oxidative stress-mediated liver damage. As an effective fi ghter 
against oxidative stress, sulforaphane provided similar neopterin 
levels as the control group, by preventing acetaminophene-induced 
hepatocellular damage. We expect positive results in case sulfora-
phane is added in the treatment protocol of acetaminophen-induced 
hepatotoxicity. Optimal treatment strategies are not available yet, 
particularly in the prevention of toxic effects due to drug-induced 
toxic hepatitis, and we believe that further studies are needed on 
this topic. In addition, we believe neopterin can be used as a prom-
ising biomarker in the acetaminophen-induced hepatotoxicity.
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